Latham & Watkins Advises on Immunovant’s Pricing of US$450 Million Common Stock Financing

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, has announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately US$450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions. All of the shares are to be sold by Immunovant.

Latham & Watkins LLP represents the underwriters and placement agents in the financing, with a capital markets team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associates Egzon Sulejmani and Jie Lin Nai.